SEC Company Response from Aura Biosciences, (AURA) — Nov 3, 2022
Aura Biosciences, Inc.
Date: Nov. 3, 2022 · CIK: 0001501796 · Accession: 0001193125-22-276950
AI Filing Summary & Sentiment
File numbers found in text: 333-268105
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Ada D. Sarmento Re: Aura Biosciences, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-268105
Dear Ada D. Sarmento,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Aura Biosciences, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 7, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570 1927.
If you have any questions regarding this request, please contact Danielle Lauzon of Goodwin Procter LLP at (617) 570 1955 or Stephanie Richards at (617) 570 1927.
Sincerely,
AURA BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR November 3, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: Aura Biosciences, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-268105 Dear Ada D. Sarmento, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Aura Biosciences, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 7, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570 1927. If you have any questions regarding this request, please contact Danielle Lauzon of Goodwin Procter LLP at (617) 570 1955 or Stephanie Richards at (617) 570 1927. Sincerely, AURA BIOSCIENCES, INC. /s/ Elisabet de los Pinos Elisabet de los Pinos, Ph.D. President and Chief Executive Officer cc: Elisabet de los Pinos, Ph.D., Aura Biosciences, Inc. Danielle Lauzon, Esq., Goodwin Procter LLP Stephanie Richards, Esq., Goodwin Procter LLP